In March, another paper in JAMA Ophthalmology looked at optic nerve problems (NAION) among patients with Type 2 diabetes who took GLP-1 drugs
The peptide may look fine but lose biological activity entirely

follow current UK SmPC for approved indications Patient monitoring should include regular assessment of: Body weight and composition to evaluate the effectiveness of weight management therapy Blood glucose levels , particularly in patients at risk of diabetes or with pre-existing diabetes Blood pressure , as both medications can affect cardiovascular parameters Gastrointestinal symptoms , ensuring tolerability of the combination Eye examinations for people with diabetes and pre-existing retinopathy, as rapid improvement in glucose control may temporarily worsen retinopathy Practical management strategies may help optimise outcomes: Timing Wegovy injections to minimise gastrointestinal side effects Implementing dietary modifications to support weight management despite steroid-induced appetite changes Ensuring adequate protein intake to counteract potential muscle loss from corticosteroids Maintaining physical activity as tolerated to support metabolic health Informing surgical teams about Wegovy use before procedures

In this clip, Im explaining: Why GLP-1s can slow digestion and lymphatic flow How lymphatic congestion contributes to fatigue, bloating, and discomfort Why hydration and nutrient support matter while on GLP-1s How supporting lymphatic drainage helps your body move waste and fat out effectively Weight loss medications change how your body processes food and nutrients
The APRN intake at Perfect B includes a hormonal context review for all female patients starting a peptide protocol